For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Mouse BRG1 aa 200-300.
This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institute's Center for Cancer Research and the lab of Gordon Hager.
Alternative versions available: Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487. This product is a recombinant rabbit monoclonal antibody.
Anti-BRG1 antibody (Alexa Fluor® 488) [EPNCIR111A] (ab196314)
Anti-BRG1 antibody (Alexa Fluor® 647) [EPNCIR111A] (ab196535)
Anti-BRG1 antibody (HRP) [EPNCIR111A] (ab196315)
Anti-BRG1 antibody (Alexa Fluor® 594) [EPNCIR111A] (ab207052)
Anti-BRG1 antibody (Alexa Fluor® 568) [EPNCIR111A] (ab207055)
Alternative versions available:
Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab110641 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use at an assay dependent concentration.|
|WB||1/10000 - 1/50000. Predicted molecular weight: 185 kDa.|
|IP||1/10 - 1/100.|
|IHC-P||1/100 - 1/250. Antigen retrieval is recommended. Heat up to 98 °C, below boiling, and then let cool for 10-20 min.|
|ICC/IF||1/100 - 1/250.|
|Flow Cyt||Use at an assay dependent concentration.|
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: BRG1 knockout HAP1 cell lysate (20 µg)
Lane 3: K562 cell lysate (20 µg)
Lane 4: Molt-4 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab110641 observed at 185 kDa. Red - loading control, ab18058, observed at 124 kDa.
ab110641 was shown to specifically react with BRG1 when BRG1 knockout samples were used. Wild-type and BRG1 knockout samples were subjected to SDS-PAGE. ab110641 and ab18058 (loading control to Vinculin) were both diluted 1/10000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 hour at room temperature before imaging.
Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling BRG1 with purified ab110641 at 1/200 dilution(10µg/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
ChIP analysis using ab110641 binding BRG1 in mouse bone marrow derived macrophages. Cells were cross-linked for 10 minutes with formaldehyde. Samples were incubated with undiluted primary antibody for 16 hours at 4°C. Protein binding was detected using real-time PCR.
Positive control: PU.1 antibody.
Negative Control: rabbit IgG.